- GLP-1 receptor agonists like semaglutide and tirzepatide were tested in large trials that included many women, so their overall evidence base is far stronger than most peptides'.
- Even so, questions specific to female physiology, whether effects vary across the menstrual cycle, were rarely pre-specified, so this remains largely unstudied.
- One interaction is documented for tirzepatide: delayed gastric emptying can reduce the absorption of oral contraceptives, and its label advises a backup method after starting or increasing the dose.
GLP-1 receptor agonists are the rare peptide story where the evidence base is genuinely strong. Semaglutide and tirzepatide reached the market through large, well-run human trials that enrolled thousands of women, which places them in a completely different evidence class from a preclinical compound. But 'women were included' and 'the female-specific questions were answered' are not the same sentence, and the gap between them is exactly where a woman's real questions live.
This piece is about that gap. It is not dosing guidance, and it does not tell anyone whether to use these compounds. It maps what the research does and does not establish for female physiology.
What GLP-1 agonists do, briefly
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. Drugs in this class mimic it: they enhance glucose-dependent insulin release, signal satiety in the brain, and slow gastric emptying, the rate at which the stomach passes food to the small intestine. Tirzepatide adds a second target (the GIP receptor). That slowed gastric emptying matters later in this article, because it is where the one well-documented female-specific interaction comes from.
The strong part: women were in the trials
The registration programs for these compounds enrolled large numbers of women, and headline efficacy and safety results include them. This is why, on this site, semaglutide and tirzepatide carry far higher study counts and a stronger evidence grade than a compound like BPC-157. The overall data is not male-only. Credit where it is due.
The unstudied part: cycle-phase effects
Here is what those large trials generally did not do: pre-specify analyses around the menstrual cycle. Appetite, gastric emptying, and insulin sensitivity are known to shift across cycle phases under the influence of estrogen and progesterone. It is biologically reasonable to ask whether a drug acting on appetite and gastric emptying interacts with those fluctuations, whether effects or side effects differ in the luteal versus follicular phase, for instance. That question was largely not the object of study. So the honest label for cycle-phase effects is unstudied: not shown to matter, not shown not to matter, simply not measured at the resolution the question needs.
This is the recurring shape of female peptide evidence, even at its best. The population was represented; the sex-specific mechanism was not interrogated. Representation in the sample is not the same as a pre-specified question in the protocol.
The documented interaction: oral contraceptives
There is one female-specific interaction that is not unstudied, and it is important. Because these drugs slow gastric emptying, they can change how quickly an oral contraceptive pill is absorbed. For tirzepatide, the approved product labeling advises that oral contraceptives may be less effective and recommends using a barrier method (or switching to a non-oral contraceptive) for a defined window after starting the drug and after each dose increase. This is a documented, label-level interaction, not an extrapolation.
The contraceptive interaction above is a documented fact from product labeling, included because it is a concrete female-specific finding. It is not a recommendation, and it is not a substitute for the guidance of a clinician and pharmacist who know your situation. Decisions about contraception and any prescribed medication belong in that conversation.
Reading the class honestly
Put together, the GLP-1 picture for women has three layers, and keeping them distinct is the whole skill. There is strong shared evidence, women were studied, and broad efficacy and safety data apply. There is a documented sex-specific interaction, the contraceptive-absorption effect, which is established for tirzepatide. And there is a genuine unstudied zone, cycle-phase modulation, which remains an open question the trials were not designed to answer.
A weaker site would blur those layers into a single reassuring paragraph. The value of separating them is that a woman can see exactly which of her questions the research has answered, which it has answered specifically for her, and which it has left open, and can take that map into a conversation with a clinician rather than a forum. The profiles for semaglutide and tirzepatide hold the structured detail behind each layer.